CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial Low Endothelial Shear Stress Predicts Evolution to High-Risk Coronary Plaque Phenotype in the Future: A Serial Optical Coherence Tomography and Computational Fluid Dynamics Study Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention Guideline Update on Indications for Transcatheter Aortic Valve Implantation Based on the 2020 American College of Cardiology/American Heart Association Guidelines for Management of Valvular Heart Disease Stroke Complicating Infective Endocarditis After Transcatheter Aortic Valve Replacement Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification Antithrombotic Management of Elderly Patients With Coronary Artery Disease Coronary Atherosclerotic Precursors of Acute Coronary Syndromes Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club
|<<... 132 133 134 135 136 137 138 ...>>|

Review Article2014 Mar;35(11):691-700.

JOURNAL：Eur Heart J. Article Link

Pulmonary hypertension related to congenital heart disease: a call for action

Dimopoulos K, Wort SJ, Gatzoulis MA. Keywords: advanced therapies; congenital heart disease; eisenmenger syndrome; pulmonary hypertension; pulmonary vascular disease; targeted therapies; treat and repair

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top